Extra immunotherapy doses may strengthen prostate cancer fight
NCT ID NCT05806814
First seen Mar 22, 2026 · Last updated May 08, 2026 · Updated 6 times
Summary
This early-phase study tests whether giving extra doses of the immunotherapy drug Sipuleucel-T can create a stronger immune response against advanced prostate cancer that has spread and no longer responds to hormone therapy. About 13 men will receive three infusions over 14 weeks. The goal is to see if the extended schedule is safe and boosts the body's ability to attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.